2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction

M McDonald, S Virani, M Chan, A Ducharme… - Canadian Journal of …, 2021 - Elsevier
In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week

SJ Greene, J Bauersachs, JJ Brugts… - Journal of the American …, 2023 - jacc.org
Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the …

M Metra, D Tomasoni, M Adamo… - European Journal of …, 2023 - Wiley Online Library
Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

[HTML][HTML] Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН) …

ВЮ Мареев, ИВ Фомин, ФТ Агеев, ЮЛ Беграмбекова… - Кардиология, 2018 - lib.ossn.ru
1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …

Heart failure drug treatment—inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)

G Savarese, T Kishi, O Vardeny, S Adamsson Eryd… - Heart Failure, 2023 - jacc.org
Background Guidelines recommend early initiation of multiple guideline-directed medical
therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and …

Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction

DD Berg, PS Jhund, KF Docherty, SA Murphy… - JAMA …, 2021 - jamanetwork.com
Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

[HTML][HTML] 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of …

SM Hollenberg, L Warner Stevenson, T Ahmad… - Journal of the American …, 2019 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Heart failure drug treatment

P Rossignol, AF Hernandez, SD Solomon, F Zannad - The Lancet, 2019 - thelancet.com
Heart failure is the most common cardiovascular reason for hospital admission for people
older than 60 years of age. Few areas in medicine have progressed as remarkably as heart …